Recruiting
Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Ulcerative Colitis (UC) - IM011-024
Updated: 01 July, 2019 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Location(s)
Recruiting
Treatment Options
Inclusion Criteria: - Documented diagnosis of UC at least 12 weeks prior to screening - Active UC with an an adapted Mayo score of 5 to 9 points, endoscopic subscore of >= 2 - Demonstrated an inadequate response, loss of response, or intolerance to at lease one of the following treatments including, 5-aminosalicylic acids (ASAs), corticosteroids, immunosuppressants, anti-tumor necrosis factor (TNF)-α agents, integrin inhibitor Exclusion Criteria: - Participant with current diagnosis of Crohn's disease (CD) or diagnosis of indeterminate colitis (IC), ischemic colitis, pseudomembranous colitis - Current evidence of fulminant colitis, abdominal abscess, toxic megacolon, or bowel perforation - History or evidence of any extensive colonic resection, subtotal or total colectomy, with or without presence of a stoma or ileoanal pouch.
